Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
HIV, Tat and dopamine transmission
Neurobiology of disease, v 105
01 Sep 2017
PMID: 28457951
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Human Immunodeficiency Virus (HIV) is a progressive infection that targets the immune system, affecting more than 37 million people around the world. While combinatorial antiretroviral therapy (cART) has lowered mortality rates and improved quality of life in infected individuals, the prevalence of HIV associated neurocognitive disorders is increasing and HIV associated cognitive decline remains prevalent. Recent research has suggested that HIV accessory proteins may be involved in this decline, and several studies have indicated that the HIV protein transactivator of transcription (Tat) can disrupt normal neuronal and glial function. Specifically, data indicate that Tat may directly impact dopaminergic neurotransmission, by modulating the function of the dopamine transporter and specifically damaging dopamine-rich regions of the CNS. HIV infection of the CNS has long been associated with dopaminergic dysfunction, but the mechanisms remain undefined. The specific effect(s) of Tat on dopaminergic neurotransmission may be, at least partially, a mechanism by which HIV infection directly or indirectly induces dopaminergic dysfunction. Therefore, precisely defining the specific effects of Tat on the dopaminergic system will help to elucidate the mechanisms by which HIV infection of the CNS induces neuropsychiatric, neurocognitive and neurological disorders that involve dopaminergic neurotransmission. Further, this will provide a discussion of the experiments needed to further these investigations, and may help to identify or develop new therapeutic approaches for the prevention or treatment of these disorders in HIV-infected individuals. (C) 2017 Elsevier Inc. All rights reserved.
Metrics
Details
- Title
- HIV, Tat and dopamine transmission
- Creators
- Peter J. Gaskill - Drexel UniversityDouglas R. Miller - University of FloridaJoyonna Gamble-George - University of FloridaHideaki Yano - National Institute on Drug AbuseHabibeh Khoshbouei - University of Florida
- Publication Details
- Neurobiology of disease, v 105
- Publisher
- Elsevier
- Number of pages
- 23
- Grant note
- NS071122 / National Institutes on Neurological Disease and Stroke R01NS071122 / NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS) DA039005; DA026947S1; DA026947 / National Institutes of Drug Abuse; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA) R01DA039005 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission OD020026; DA043895 / Office of Research Infrastructure Program S10OD020026 / OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000406734300005
- Scopus ID
- 2-s2.0-85019983780
- Other Identifier
- 991019167849204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Neurosciences